Premium
Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy
Author(s) -
Niesvizky Ruben,
Naib Tara,
Christos Paul J.,
Jayabalan David,
Furst Jessica R.,
Jalbrzikowski Jessica,
Zafar Faiza,
Mark Tomer,
Lent Richard,
Pearse Roger N.,
Ely Scott,
Leonard John P.,
Mazumdar Madhu,
ChenKiang Selina,
Coleman Morton
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06698.x
Subject(s) - lenalidomide , medicine , dexamethasone , multiple myeloma , hazard ratio , adverse effect , renal function , oncology , creatinine , confidence interval , urology , gastroenterology
Summary Data on 72 patients receiving lenalidomide/dexamethasone for multiple myeloma (MM) was used to determine the factors that are associated with lenalidomide‐induced myelosuppression. Eight of 14 patients with grade ≥3 myelosuppression had baseline creatinine clearance (CrCl) ≤0·67 ml/s. Kaplan–Meier analysis by log‐rank test demonstrated a significant association ( P < 0·0001) between renal insufficiency and time to myelosuppression (hazard ratio = 8·4; 95% confidence interval 2·9–24·7, P = 0·0001). Therefore, CrCl is inversely associated with significant myelosuppression. Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients.